Jacob's learnings
1. Capital efficiency as competitive advantage
In the current biotech environment, in which investors remain selective and buyers are prioritizing high-quality assets, capital efficiency has become a competitive advantage. The question is no longer simply whether companies can raise money. It's whether they can deploy that money effectively as they prepare for launch.
2. Commercial readiness is shifting left in the development timeline
Commercial decisions, like patient segmentation or payer strategy, influence clinical-development decisions. With clinical trials becoming shorter, and regulatory pathways faster, companies can't wait until Phase 3 to start thinking about GTM. Commercial is being brought into strategic discussions much earlier.
3. The trust problem around data is in commercial ops’ wheelhouse
Today’s challenge isn't about acquiring more data but establishing a trusted source of truth. Commercial organizations need to identify the data that’s fit for purpose, understand what's behind it, and build confidence in the insights it generates.
4. IT infrastructure-building should start earlier, too
Infrastructure is often treated as downstream from strategy. But it determines whether strategy works at all. Data warehouses, CRM systems, and field coordination tools need enough lead time to be tested and trusted before the first sale.
Bottom line:
Commercial ops increasingly influences where companies invest, which data they trust, and how they prepare for launch. Those decisions happen long before execution begins, placing the function closer to the center of organizational decision-making.